Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Incyte Corporation INCY

Healthcare  —  Biotechnology
123.20 (1.62) (1.30%) as of 29 Sep
Market cap
$26.1B
P/E
15.4×
S&P 500 Member Revenue Champion (10y)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Incyte Corporation (INCY) Price to free cash flow

As of 28 September 2026, Incyte Corporation (INCY) trades at a price to free cash flow of 13.2×. Over the past ten years it has ranged from 0.0× (September 2024) to 956× (November 2024); the current reading is higher than 25% of that period. That is below the Biotechnology industry median of 21.1× and below the Healthcare sector median of 19.9×.

Price to free cash flow, daily

Annual

Period Price to free cash flow Change
FY2025 14.5× (76.16%)
FY2024 60.8× 86.60%
FY2023 32.6× 64.67%
FY2022 19.8× (30.44%)
FY2021 28.5× —
FY2020 0.0× —
FY2019 29.7× (42.29%)
FY2018 51.4× —
FY2017 0.0× —
FY2016 104× (66.08%)

Quarterly

Period Price to free cash flow Change
Jun 2026 12.0× (9.01%)
Mar 2026 13.2× (8.94%)
Dec 2025 14.5× 2.41%
Sep 2025 14.2× 1.34%
42 more quarters

Against its own ten years

Low 0.0× High 956×
Ten-year median 26.4×
Current reading's percentile 25

Price to free cash flow against peers

Company Price to free cash flow
GMAB Genmab A/S Sponsored ADR compare n/m
ROIV Roivant Sciences Ltd. compare n/m
INSM Insmed, Inc. compare n/m
JAZZ Jazz Pharmaceuticals PLC compare 10.6×
INCY Incyte Corporation 13.2×
RPRX Royalty Pharma PLC compare 19.8×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 31.3×
ALNY Alnylam Pharmaceuticals, Inc. compare 41.6×
BNTX BioNTech SE Sponsored ADR compare 50.2×
Biotechnology industry median 21.1×
Healthcare sector median 19.9×
Market median 13.9×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on INCY